CervoMed's dementia drug fails to meet mid-stage trial goals (updated)
10/12/2024 12:30
(Adds details on disease and trial throughout)
Dec 10 (Reuters) -
U.S. drug developer CervoMed CRVO.O said on Tuesday its
experimental drug for a common degenerative brain disease did
not meet the main or secondary goals in a mid-stage clinical
trial.
The drug, neflamapimod, did not achieve the trial's main
goal of significantly reducing symptoms of dementia, but the
company said it believed the treatment had potential and would
investigate the reasons for the results.
CervoMed was testing neflamapimod as a treatment for a form
of dementia caused by the accumulation of protein deposits
called Lewy bodies in the brain's nerve cells.
Shares of the company were halted in premarket hours.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil
D'Silva and Devika Syamnath)
((Kamal.Choudhury@thomsonreuters.com;))